Endocrine Cancers Clinical Research

The Program in Endocrine Malignancies is dedicated to the diagnosis and therapy of benign and malignant tumors of the endocrine glands. The physicians affiliated with this center have expertise in the diagnosis and treatment of benign and malignant tumors of the thyroid, parathyroid, and adrenal glands as well as the tumors of the endocrine pancreas.


Research Summary

Genetic syndromes that affect these organs are a particular interest. An independent Neuroendocrine Center specializes in tumors of the pituitary and hypothalamus.

Diagnostic studies include:

  • Fine needle aspiration biopsies and ultrasound-guided fine needle aspiration biopsies of thyroid nodules
  • Radioiodine and technetium scanning of the thyroid glands
  • Sestimibi scanning of the parathyroid glands
  • Whole body radioiodine scanning and the use of recombinant human TSH for whole body scanning
  • Transduodenal biopsies of pancreatic neuroendocrine tumors
  • Adrenal vein catheterization
  • MIBG and PET scanning

Our surgeons are highly skilled at performing total thyroidectomy and neck dissections for well-differentiated thyroid carcinoma and medullary thyroid carcinoma, tracheal resection for invasive thyroid carcinoma, minimally invasive parathyroid surgery and laparascopic surgery for adrenal tumors. Radioactive iodine therapy for well-differentiated thyroid is a particular interest. Protocols are available for therapy of advanced thyroid carcinoma.

Our group is actively involved in the National Thyroid Cancer Treatment Cooperative Registry as well as the National Comprehensive Cancer Network Thyroid Carcinoma Clinical Practice Guidelines in Oncology.

Group Members


1 Herraiz M, Barbesino G, Faquin W, Chan-Smutko G, Patel D, Shannon KM, Daniels GH, Chung DC Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol. 03/19/2007; 5(3); 367-73.

2 Faris JE, Moore AF, Daniels GH Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid. 11/30/2007; 17(11); 1147-9.

3 Sherman SI, Angelos P, Ball DW, Beenken SW, Byrd D, Clark OH, Daniels GH, Dilawari RA, Ehya H, Farrar WB, Gagel RF, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Ridge JA, Robbins R, Shah JP, Sisson JC, Thompson NW, Thyroid carcinoma. J Natl Compr Canc Netw. 07/08/2005; 3(3); 404-57.

4 Randolph GW, Daniels GH Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. Thyroid. 12/19/2002; 12(11); 989-96.

5 Wunderbaldinger P, Harisinghani MG, Hahn PF, Daniels GH, Turetschek K, Simeone J, O'Neill MJ, Mueller PR Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol. 02/21/2002; 178(3); 693-7.

6 Daniels GH Radioiodine and thyroid cancer: some questions, controversies, and considerations. Endocr Pract. 08/10/2001; 7(4); 320-3.

7 Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 11/26/1999; 84(11); 3877-85.

8 Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer. Thyroid. 03/17/2008; 18(3); 317-23.

Back to Top